RxDoctor Payments Data

Elias Kfoury, MD

Surgery · Cheyenne, WYNPI 1841422094

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $7,000 of the $8,866 with a category attached, or 79.0%. Penumbra, Inc. accounts for 79.0% of it on its own, with 19 other manufacturers making up the rest. 2025 is the largest year on record at $8,113, more than ten times the $129 reported in 2019.

$8,866in general payments, 2019–2025

Across 42 payments — averaging $211.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Penumbra, Inc.$7K
  • W. L. Gore & Associates, Inc.$1K
  • Boston Scientific$127
  • Endologix LLC$45
  • Novo Nordisk$42
  • Cook Medical LLC$35
  • plus $256 from 14 others

What the payments were for

  • Speaking & faculty fees$7,00079%
  • Travel & lodging$1,09612%
  • Food & beverage$7699%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,866 in reported general payments places this provider in the 75th percentile of 49 surgery providers in Wyoming.

See all surgery providers in Wyoming

Medicare billing

Part B allowed, 2024
$287,385
Medicare patients
466
Services billed
1,658

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban23$30,515
BrilintaTicagrelor13$10,135
ClopidogrelClopidogrel Bisulfate184$1,642
Atorvastatin Calcium62$573
Cilostazol21$341
Rosuvastatin Calcium14$277
Warfarin Sodium18$80

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$12$30,51523 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 49 surgery providers in Wyoming.

Other surgery in Cheyenne

See the full list for Wyoming

Where these figures come from

Is this you, or does something look wrong? →